Sino Biopharmaceutical Ltd. (HKG: 1177) announced it has agreed to acquire a 100 % equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB 1.2 billion (USD 172 million), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.
Deal Structure
Item
Detail
Acquirer
Sino Biopharmaceutical Ltd. (HKEX: 1177)
Target
Hygieia Pharmaceuticals (private)
Equity
100 % stake
Base Consideration
RMB 1.2 billion (USD 172 million)
Structure
All‑cash transaction
Payment
To be completed upon regulatory approvals (expected Q2 2026)
Earn‑out
Up to RMB 300 million in milestones tied to Phase III initiation and NDA approvals
Target Profile & siRNA Platform
Technology:Small interfering RNA (siRNA) platform enabling long‑lasting target gene silencing with single or infrequent administrations
Therapeutic Areas:
Weight loss/metabolism
Cardiovascular/cerebrovascular
Nervous system disorders
Pipeline:4 clinical‑stage assets and 10+ preclinical molecules with first‑in‑class (FIC) or best‑in‑class (BIC) potential
Core Pipeline Assets
Drug
Target
Dosing
Indication
Stage
Kylo‑11
Lp(a) siRNA
Once yearly
Cardiovascular disease
Phase II
Kylo‑12
APOC3 siRNA
Every 6 months
Hypertriglyceridemia (HTG), FCS
Phase II‑ready
Preclinical
Undisclosed siRNA
Once yearly
Obesity
Preclinical
Preclinical
Undisclosed siRNA
Every 6 months
Alzheimer’s disease
Preclinical
Market Opportunity & Competitive Landscape
Parameter
China
Global
Hyperlipidemia Patients (Lp(a) elevation)
25 million
90 million
Severe HTG/FCS Patients
1.2 million
4.5 million
Obesity (Class II/III)
85 million
650 million
Alzheimer’s Disease
10 million
55 million
siRNA Market (2030E)
¥28 billion
$18 billion
Hygieia Peak Revenue (2032E)
¥4.2 billion
$2.8 billion
Competitive Moat: Hygieia’s ultra‑long‑acting dosing (once yearly for Lp(a), every 6 months for APOC3) vs. competitors requiring monthly or quarterly injections (e.g., Novartis’s Leqvio)
Strategic Value: Acquisition provides Sino Biopharmaceutical with first‑in‑China siRNA platform, leapfrogging domestic competitors in chronic disease RNA therapeutics
Manufacturing: Sino’s Shanghai biologics facility will integrate Hygieia’s siRNA conjugation and LNP formulation capabilities by 2027
Commercial Reach: Sino’s 3,000‑person sales force targeting tier‑2/3 hospitals can rapidly launch Kylo‑11/12 upon approval
Global Ambitions: Hygieia’s platform enables ex‑China licensing to MNCs; Sino plans US IND filings for Kylo‑11 in 2027
Forward‑Looking Statements This brief contains forward‑looking statements regarding acquisition completion, pipeline development timelines, and revenue forecasts for Hygieia’s siRNA platform. Actual results may differ due to regulatory approval timelines, clinical trial outcomes, and competitive dynamics in the RNA therapeutics market.-Fineline Info & Tech
By Fineline Cube